4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lactylation in cancer: Mechanisms in tumour biology and therapeutic potentials

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lactylation, a recently identified form of protein post‐translational modification (PTM), has emerged as a key player in cancer biology. The Warburg effect, a hallmark of tumour metabolism, underscores the significance of lactylation in cancer progression. By regulating gene transcription and protein function, lactylation facilitates metabolic reprogramming, enabling tumours to adapt to nutrient limitations and sustain rapid growth. Over the past decade, extensive research has revealed the intricate regulatory network underlying lactylation in tumours. Large‐scale sequencing and machine learning have confirmed the widespread occurrence of lactylation sites across the tumour proteome. Targeting lactylation enzymes or metabolic pathways has demonstrated promising anti‐tumour effects, highlighting the therapeutic potential of this modification. This review comprehensively explores the mechanisms of lactylation in cancer cells and the tumour microenvironment. We expound on the application of advanced omics technologies for target identification and data modelling within the lactylation field. Additionally, we summarise existing anti‐lactylation drugs and discuss their clinical implications. By providing a comprehensive overview of recent advancements, this review aims to stimulate innovative research and accelerate the translation of lactylation‐based therapies into clinical practice.

          Key points

          • Lactylation significantly influences tumour metabolism and gene regulation, contributing to cancer progression.

          • Advanced sequencing and machine learning reveal widespread lactylation sites in tumours.

          • Targeting lactylation enzymes shows promise in enhancing anti‐tumour drug efficacy and overcoming chemotherapy resistance.

          • This review outlines the clinical implications and future research directions of lactylation in oncology.

          Abstract

          • Lactylation significantly influences tumour metabolism and gene regulation, contributing to cancer progression.

          • Advanced sequencing and machine learning reveal widespread lactylation sites in tumours.

          • Targeting lactylation enzymes shows promise in enhancing anti‐tumour drug efficacy and overcoming chemotherapy resistance.

          • This review outlines the clinical implications and future research directions of lactylation in oncology.

          Related collections

          Most cited references179

          • Record: found
          • Abstract: found
          • Article: found

          Hallmarks of Cancer: The Next Generation

          The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Hallmarks of Cancer: New Dimensions

            The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity of cancer phenotypes and genotypes into a provisional set of underlying principles. As knowledge of cancer mechanisms has progressed, other facets of the disease have emerged as potential refinements. Herein, the prospect is raised that phenotypic plasticity and disrupted differentiation is a discrete hallmark capability, and that nonmutational epigenetic reprogramming and polymorphic microbiomes both constitute distinctive enabling characteristics that facilitate the acquisition of hallmark capabilities. Additionally, senescent cells, of varying origins, may be added to the roster of functionally important cell types in the tumor microenvironment. SIGNIFICANCE: Cancer is daunting in the breadth and scope of its diversity, spanning genetics, cell and tissue biology, pathology, and response to therapy. Ever more powerful experimental and computational tools and technologies are providing an avalanche of "big data" about the myriad manifestations of the diseases that cancer encompasses. The integrative concept embodied in the hallmarks of cancer is helping to distill this complexity into an increasingly logical science, and the provisional new dimensions presented in this perspective may add value to that endeavor, to more fully understand mechanisms of cancer development and malignant progression, and apply that knowledge to cancer medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Understanding the tumor immune microenvironment (TIME) for effective therapy

              The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical response with immunotherapeutic intervention; however, many more patients have experienced minimal or no clinical benefit when provided the same treatment. As technology has advanced, so has the understanding of the complexity and diversity of the immune context of the tumor microenvironment and its influence on response to therapy. It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and therapy; by parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.
                Bookmark

                Author and article information

                Contributors
                1025931346@qq.com
                urology1969@aliyun.com
                Journal
                Clin Transl Med
                Clin Transl Med
                10.1002/(ISSN)2001-1326
                CTM2
                Clinical and Translational Medicine
                John Wiley and Sons Inc. (Hoboken )
                2001-1326
                25 October 2024
                November 2024
                : 14
                : 11 ( doiID: 10.1002/ctm2.v14.11 )
                : e70070
                Affiliations
                [ 1 ] Department of Urology Renmin Hospital of Wuhan University Wuhan Hubei P.R. China
                Author notes
                [*] [* ] Correspondence

                Fan Cheng and Weimin Yu, Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, P.R. China.

                Email: urology1969@ 123456aliyun.com ; 1025931346@ 123456qq.com

                Author information
                https://orcid.org/0000-0002-3471-6221
                Article
                CTM270070
                10.1002/ctm2.70070
                11511673
                39456119
                b3dc36b3-75b1-485f-b560-583a6007080d
                © 2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 03 October 2024
                : 06 August 2024
                : 10 October 2024
                Page count
                Figures: 7, Tables: 3, Pages: 23, Words: 12898
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: #82100806
                Award ID: #82170775
                Award ID: #82270802
                Award ID: #82300766
                Award ID: #82370765
                Award ID: #82372966
                Categories
                Review
                Review
                Custom metadata
                2.0
                November 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.9 mode:remove_FC converted:26.10.2024

                Medicine
                clinical translation,lactylation,post translational modification,tumour biology,tumour microenvironment

                Comments

                Comment on this article